Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer (ALPINE)

This study has been completed.
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc. Identifier:
First received: July 11, 2012
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)